Fundraising Fox

Oberland Capital

Venture debt

New York · Growth–Late Stage · 20 people tracked

Also known as OBERLAND CAPITAL MANAGEMENT LLC

Fox Verdict
Sign up to see your fit

Investment thesis

Oberland Capital is a dedicated healthcare investor that specializes in customized, flexible investment structures for clinical-stage and commercial-stage companies. It applies a fundamental, research-driven approach combined with quantitative methods to back innovative technologies aimed at improving patient outcomes worldwide. The firm focuses on the pharmaceutical, biotechnology, medical device, and diagnostic sectors, collaborating with management teams to create tailored financing that helps them access significant capital for accelerating R&D, expanding commercial infrastructure, acquiring assets or companies, and refinancing existing capital sources. Its partners span public and private companies, research institutions, and individual inventors, and it executes structured investments globally.

Source: firm website, verified Jul 31, 2026.

Stage
Growth–Late Stage
Check
$50M – $300M
HQ
New York, NY, US
Instruments
Equity · Debt
Founded
2013
AUM
$3.2B
Tracked investments
1

Team · 20 people

from the firm's website
Andrew Rubinstein· Managing Partner

Managing Partner who previously co-managed Paul Capital's healthcare royalty platform and was CEO of Microban International. Earned a J.D. and M.B.A. from NYU and a B.A. from the University of Pennsylvania.

Jean-Pierre Naegeli· Managing Partner

Managing Partner who previously co-managed Paul Capital's healthcare royalty platform and spent nearly a decade at Johnson & Johnson, including principal investing at J&J Development Corporation. Holds a Masters from Yale School of Management and an engineering diploma from the Swiss Federal Institute of Technology.

Cecilia Gonzalo· Partner

Partner who previously held Managing Director roles at Vatera Healthcare Partners, Essex Woodlands, and Warburg Pincus, and began her career at Goldman Sachs. Earned an M.B.A. and A.B. from Harvard.

Michael Bloom· Partner

Partner who was previously an investment professional at Paul Capital and a healthcare consultant at the Frankel Group. Holds an M.B.A. from Wharton and a B.A. from Colby College.

Sarah Siber· Partner

Partner who was previously a Senior Manager in Corporate Development at Pfizer and an analyst at Blackstone and Oppenheimer. Holds an M.B.A. from Columbia and a B.S. from Cornell.

William Clifford· Partner

Partner who was previously an investment professional at Paul Capital and a strategy consultant at Health Advances. Holds an M.S. in Biochemistry from Georgetown and a B.A. from Kenyon College.

Sean Fillion· Principal

Principal who was previously in strategy and corporate development at Siemens Healthineers and an investment banking associate at Greenhill. Holds an M.B.A. from Harvard and a B.S. from the University of Virginia.

Allie Southard· Chief Accounting Officer

Chief Accounting Officer who was previously a Senior Manager in EY's asset management assurance practice. Holds an M.S. and B.S. in Accountancy from Wake Forest and is a CPA.

Brandon Holtrup· Senior Vice President

Senior Vice President who previously worked in Global Analytics at AstraZeneca and as a consultant at L.E.K. Holds a PhD from Yale and a B.S. from DePaul University.

Christine Yang· Controller

Controller who was previously a Manager in PwC's asset and wealth management assurance practice. Holds an M.S. and B.S. in Accounting from the University of Virginia and is a CPA.

David Dubinsky· Chief Financial Officer

CFO who was previously Managing Director and CFO at Siguler Guff & Company and a manager at Ernst & Young. Holds a B.S. in Accounting from Binghamton University and is a CPA.

James James· Managing Director of Business Development and Investor Relations

Leads business development and investor relations, having previously worked at Gladius Capital Management, Utah Retirement Systems, and BlackRock. Holds a B.S. in Physics from Brigham Young University.

Jing Qiu· Senior Associate

Senior Associate who was previously a business development associate at Rejuveron Life Sciences and a consultant at ClearView. Holds a PhD in Genetics from Yale and a B.S. from the University of Virginia.

Johannes Lauenstein· Vice President

Vice President who was previously a project leader at Boston Consulting Group. Holds a PhD from the University of Cambridge and degrees in biochemistry from Ghent University.

Johnna Schifilliti· Director of Operations

Director of Operations who previously led private equity marketing at KPMG and began her career in KPMG's audit practice. Holds a B.S. in Accountancy from Villanova University.

Joseph Borrero· Deputy Chief Compliance Officer and Associate General Counsel

Deputy CCO and Associate General Counsel who was previously a compliance officer at Goldman Sachs and a litigation associate at Paul, Weiss. Holds a J.D. from George Washington and a B.A. from SUNY Albany.

Kristian Wiggert· General Counsel and Chief Compliance Officer

General Counsel and CCO who was previously a Partner in the life sciences practices at Covington & Burling and Morrison & Foerster. Holds a J.D. from Harvard Law and an A.B. from Columbia College.

Molly Scott· Senior Vice President

Senior Vice President who was previously a consultant at ClearView Healthcare Partners and completed a PhD at Yale. Holds a B.A. from Amherst College.

Paul Tabor· Senior Associate

Senior Associate who previously spent 13 years at CU Innovations in strategy, business development and licensing, and earlier at Baylor College of Medicine. Holds an M.B.A. from UT Austin and degrees from Baylor University.

Trish Blair· Senior Administrative Coordinator

Senior Administrative Coordinator who was previously Operations Manager for The Actors Green Room. Holds a B.A. in Music Performance from Winthrop University.

Investments · 1 tracked

founders shown can be your intro path
Opus Geneticsopusgtx.comin

Fund performance · per public LP disclosures · 3

as of Dec 2025
FundVintageCommittedNet IRRTVPIDPI
Oberland Capital Healthcare III LP2.9%1.11x0.19x
Oberland Capital Healthcare Solutions Co-Invest LP23.5%1.35x0.56x
Oberland Capital Healthcare Solutions LP10.6%1.22x0.58x

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

Frequently asked questions

What stage does Oberland Capital invest at?
Oberland Capital invests at the Growth, Late Stage stages.
What is Oberland Capital's typical check size?
Oberland Capital typically writes checks of $50M – $300M.
What sectors does Oberland Capital focus on?
Oberland Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is Oberland Capital located?
Oberland Capital is headquartered in New York, US.

Similar investors

Featured in lists